caused injury to central catecholaminergic neurons, as indicated by a reduction of tyrosine hydroxylase (TH) immunoreactivity in the substantia nigra (SN), ventral tegmental area (VTA) and olfactory bulb (OB), and brain noradrenergic neurons, as indicated by a reduction of TH immunoreactivity in the locus coeruleus (LC) of the P21 rat brain. The LPSinduced reduction of TH+ cells was observed at a greater degree in the SN and LC of the P21 rat brain. Intranasal rhIGF-1 treatment attenuated LPS-induced central catecholaminergic neuronal injury and motor behavioral disturbances, including locomotion, beam walking test and gait analysis. Intranasal rhIGF-1 administration also attenuated LPS-induced elevation of IL-1β levels and numbers of activated microglia, and cyclooxygenase-2+ cells, which were double labeled with TH+ cells in the SN, VTA, OB and LC of the P21 rat brain. These results suggest that IGF-1 may provide protection against neonatal LPS exposure-induced central catecholaminergic neuronal injury and motor behavioral disturbances, and that the protective effects are associated with the inhibition of microglia activation and the reduction of neuronal oxidative stress by the suppression of the neuronal cyclooxygenase-2 expression.
Introduction
Increasing evidence has indicated that perinatal infection/inflammation not only is a major contributor to brain injury in newborns, but also has long-term consequences and could speculatively modify the risk of a variety of neurological disorders in children and adults. Perinatal exposure to an endotoxin, lipopolysaccharide (LPS), a component of the cell wall of gram-negative bacteria [1] , has been shown to increase the risk of dopaminergic disorders in animal models of Parkinson disease [2, 3] . In our previous studies, we developed a neonatal rat model of central exposure to LPS through an intracerebral injection in postnatal day 5 (P5) rats (the brain development in P2-P7 rats is compatible with that of preterm infants at 23-32 gestation weeks) [4] to study nigrostriatal dopaminergic neuronal injury associated with the infection/inflammation in the immature brain [2, 5, 6] . Neonatal LPS treatment causes functional disability, such as sensory, motor, emotional and cognitive impairment in juvenile rats (P21), suggesting possible involvement of dopaminergic impairment in this neonatal rat model of central inflammation-induced neurological dysfunction [5, 6] .
Insulin-like growth factor-1 (IGF-1) is a trophic factor produced in the liver and the central nervous system including neurons and glial cells [7] . The IGF-1 level in cerebral spinal fluid (CSF) is greater during early brain development, which indicates an important role in brain development, neuronal growth promotion, cellular proliferation and differentiation, especially during myelination and synapse formation in the developing nervous system [8, 9] . IGF-1 also has autocrine functions in the brain and contributes to the control of neuronal excitability, nerve cell metabolism and cell survival [10] . Therefore, IGF-1 is considered to have multiple neuroprotective properties in the adult brain [10, 11] . In addition, IGF-1 shows anti-inflammatory action by the reduction of LPS-induced brain cytokine expression via the downregulating of glia activation and inducing of an endogenous growth factor [12, 13] . Intranasal administration provides a noninvasive method which may bypass the blood-brain barrier (BBB) to deliver therapeutic agents to the central nervous system, and thus reducing systemic exposure and side effects [14, 15] . Studies by us and others have shown that IGF-1 can be delivered to the rodent brain along olfactory and trigeminal pathways with intranasal administration [14, 15] , and that intranasally delivered IGF-1 protects against LPS-induced white matter injury in the developing rat brain [16] , cerebral hypoxic-ischemic injury [17] [18] [19] , and other neurodegenerative damages [20, 21] which may be related to activation of intracellular signaling cascades such as the phosphatidylinositol-3 kinase/Akt pathway [20] [21] [22] [23] .
Our previous studies have revealed that neonatal exposure to LPS at P5 in rats produces chronic inflammation and injury in the nigrostriatal dopaminergic system [5, 6] . The LPS-induced neuroinflammation and neurobehavioral dysfunction are involved not only in the substantia nigra (SN) [23, 24] , but also in other central catecholaminergic neurons such as the dopaminergic neurons in the ventral tegmental area (VTA) of the midbrain [23, 25] and olfactory bulb (OB) [26, 27] , and the noradrenergic neurons in the locus coeruleus (LC) of the pons [23, 24] . The objective of the present study is to further examine whether IGF-1 delivered through the intranasal route in the neonatal rat provides longlasting protection against LPS-induced dopaminergic and noradrenergic neuronal injury, and ameliorates LPS-induced neurobehavioral dysfunction in juvenile rats.
Materials and Methods

Chemicals
Unless otherwise stated, all chemicals used in this study were purchased from Sigma (St. Louis, MO, USA). Recombinant human IGF-1 (rhIGF-1) was purchased from R & D Systems (Minneapolis, MN, USA). Monoclonal mouse antibodies against neuron-specific nuclear protein (NeuN) and tyrosine hydroxylase (TH) were purchased from Millipore (Billerica, MA, USA). Polyclonal goat antibodies against cyclooxygenase-2 (COX-2) and polyclonal rabbit antibodies against ionized calcium binding adapter molecule 1 (Iba1) were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and Wako Chemicals USA (Irvine, CA, USA), respectively. ELISA kits for immunoassay of rat interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α) were purchased from R & D Systems (Minneapolis, MN, USA).
Animals
Timed pregnant Sprague-Dawley rats arrived in the laboratory on day 19 of gestation. Animals were maintained in an animal room on a 12-h light/dark cycle and at constant temperature (22 ± 2 ° C). The day of birth was defined as postnatal day 0 (P0). After birth, the litter size was adjusted to 10 pups per litter to minimize the effect of litter size on body weight and brain size. All procedures for animal care were conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use Committee at the University of Mississippi Medical Center. Every effort was made to minimize the number of animals used and their suffering.
Surgery Procedures and Animal Treatment
Intracerebral injection of LPS to 5-day-old Sprague-Dawley rat pups of both sexes was performed as previously described [5, 16] . Under light anesthesia with isoflurane (1.5%), LPS (1 mg/kg, from Escherichia coli , serotype 055: B5) in sterile saline (total volume of 2 μL) was administered to the rat brain unilaterally at the location of 1.0 mm posterior and 1.0 mm left of the bregma, and 2.0 mm deep to the skull surface in a stereotaxic apparatus with a neonatal rat adapter. The dose of LPS was chosen based on the previously reported results which produced brain injury [5, 16] . The injection site was located at the area just above the left cingulum. The control rats were injected with the same volume of sterile saline. All animals survived the intracerebral injection. Each dam had the same litter size (10 pups), and equal numbers of LPS-treated and salinetreated rat pups were included in a litter.
Intranasal administration of rhIGF-1 in the rat pup 1 h following intracerebral injection of LPS or saline was performed as previously described [16, 17] . Briefly, P5 Sprague-Dawley rat pups were placed on their backs under light anesthesia with isoflurane (5% for induction and 1.5% for maintenance). After pups had been sedated, 50 μg of rhIGF-1 dissolved in 5 μL PBS containing 0.1% BSA was given into the left naris using a fine tip. This dose of IGF-1 has been shown to protect the neonatal rat brain from LPS-induced white matter injury [16] and hypoxic-ischemic injury in our previous studies [17] . The pups remained sedated with isoflurane for 5 min to ensure that they stayed on their backs. All pups woke up within 1-2 min upon withdrawal of isoflurane and were returned to their dams. For pups in the control group, 0.1% BSA was given by intranasal administration.
One animal from each litter was included in each experimental group. Twelve pups were included in each treatment group for behavioral tests. One or sixteen days following the injection (P6 or P21), 6 pups of each group were sacrificed by decapitation for fresh brain tissue collection. One set of animals at P21 was sacrificed by transcardiac perfusion with normal saline followed by 4% paraformaldehyde for brain section preparation. Free-floating coronal brain sections at 40 μm of thickness were prepared in a sliding microtome for immunohistochemistry staining and stereological estimates of the total number of neurons in the SN, VTA, OB, and LC.
Behavioral Testing
The motor behavioral tests, including locomotion and stereotypy, gait analysis and beam walking tests were performed by an investigator blind to the treatment as described previously [2, 5, 6] with modifications.
Locomotion and Stereotypy. The open field test measures the activity and habituation response of animals on placement in a novel environment [28] . Locomotor activity was measured using the ANY-maze Tracking System (Stoelting Co., Wood Dale, IL, USA). Animals were placed in the activity chambers (42 × 25 × 40 cm 3 ) in a quiet room with dimmed light every other day from P9 to P21. The total distance traveled by the animal was recorded during a 10-min testing period. The number of rearing events was counted during the first 5-min testing period at P14 and P21. The summation of rearing responses and stereotyped behaviors reflect vertical activity which has been used apart from locomotion as a reliable criterion for motor activity during their exposure to novelty [29] . The stereotyped behaviors of standing, grooming, scratching, head-swinging, sniffing, and freezing were quantified during the first 5-min testing period at P14 and P21. Quantification of stereotyped behaviors was achieved by counting the frequency of discrete episodes, and the summation of all stereotyped responses during the testing period was scored for each rat [29] .
Beam Walking Test. Motor coordination and balance were assessed by measuring the ability of the animals to traverse a narrow beam to reach an enclosed safety platform [30] . A 60-cm-long round wood beam with a diameter of 3 cm was placed horizontally, 50 cm above the bench surface, with one end mounted on a narrow support and the other end attached to a goal box with a litter of pups. A sawdust-filled box that was placed underneath served as protection for the falling pups. A light (60 W) was positioned above the start of the beam. A litter of pups was placed in the goal box, and 1 pup at a time was removed and placed on the starting platform. Each pup was given 3 trials a day. The time spent on the beam for each pup that traversed the beam and joined its littermates was recorded and the cutoff time was 60 s.
Gait Analysis. Gait abnormalities and beam walking deficits have been conducted for the evaluation of nigrostriatal lesions in rodent models [31] . The hind paws of each rat were smeared with ink. The animal was allowed to walk up a runway (80 × 10 cm) covered with white paper that had a darkened part at the end. For motivational purposes, a white light (60 W) was placed at the beginning of the ramp. The walking task was repeated until 4 satisfactory walks of at least 4 steps without pause were obtained. Four variables from the footprint pattern were measured as follows: (1) foot length (the length of hind foot), (2) spreading of toes 1-5 (the length between toes 1-5 of hind foot), (3) stride length (distance between the successive placement of the same hind foot), and (4) stride width (the vertical distance between one hind foot and the succeeding print of the opposite hind foot).
Immunohistochemistry Studies
Free-floating coronal brain sections at 40 μm of thickness were prepared in a freezing microtome (Leica, SM2010R, Wetzlar, Germany). Primary antibodies were used with the following dilutions: NeuN (1: 300), TH (1: 1,000), COX-2 (1: 100) and Iba1 (1: 500). NeuN detects the neuron-specific nuclear protein which primarily localizes in the nucleus of the neurons with slight staining in the cytoplasm. TH (the rate-limiting synthetic enzyme for dopamine and norepinephrine) was used to detect dopaminergic neurons in the SN, VTA, and OB, and noradrenergic neurons in the LC. COX-2 provides selective staining of inducible cyclooxygenase. Microglia were detected using Iba1 immunostaining, which recognizes both the resting and the activated microglia. Sections were incubated with primary antibodies at 4 ° C overnight and further incubated with secondary antibodies conjugated with fluorescent dyes (Alexa Fluor 488 or Alexa Fluor 555, Millipore, Billerica, MA, USA; and Cy2 or Cy3, Jackson Immunoresearch, West Grove, PA, USA) for 1 h in the dark at room temperature. DAPI (100 ng/mL) was used simultaneously to stain nuclei and aid their identification during the final visualization. Sections incubated in the absence of primary antibody were used as negative controls. The resulting sections were examined under a fluorescent microscope (Nikon Ni-E, Melville, NY, USA, or Olympus BX60, Center Valley, PA, USA) at appropriate wavelengths.
Stereological Estimates of the Total Number of Cells in the Brain
The stereological estimates of the total number of TH+ neurons, NeuN+ neurons, COX-2+ cells and Iba1+ cells in 4 reference spaces (SN, VTA, OB, and LC) were performed in the P21 rat brain following the methods described previously [2, 3, 32] . Eight or 4 equally spaced thick sections (40 μm) in the midbrain and forebrain levels or pontine level that were to be used in the analysis came from a 1-in-6 series. The total number of TH+, NeuN+, COX-2+ or Iba1+ labeled cells (est N) were counted in each of the 8 or 4 sections, which cover the entire SN, VTA, OB, or LC region, respectively. We found in our previous study that FITC-labeled LPS administered through a unilateral intracerebral injection distributed quickly to both hemispheres within 0.5 h (data not shown). Furthermore, following a unilateral intracerebral injection of LPS or saline in the P5 rat brain, no significant differences in density of TH+ cells were observed between the ipsilateral (left) and the contralateral side (right) of the P21 rat brain [5] . Therefore, stereological cell counts from both sides of the rat brain were averaged and presented in the present study. Stereological cell counting in the present study was focused in the SN region (nucleus A9 cells or cells in both the SN pars compacta and the SN pars reticulata), VTA region (nucleus A10 cells or cells in VTA), OB region (nucleus A16 cells or cells in OB) and LC region (nucleus A6 cells or cells in LC). The Cavalieri principle [33] was used to estimate the reference volumes, est V ( ref ), and the volume density, est N V . The product of the 2 is an estimate of the total number of cells in this region: [3, 33] . As described previously [32] , the images were taken under unbiased conditions using Stereo Investigator software (MBF Bioscience, Williston, VT, USA) with a motorized microscope (Nikon Ni-E, Melville, NY, USA). Imaged cells were then examined and quantified with the software.
ELISA
Concentrations of IL-1β, IL-6, and TNF-α in the rat brain at 24 h or 16 days after the LPS exposure were determined as markers of LPS-induced inflammatory responses by ELISA. ELISA was performed following the manufacturer's instruction as previously described [16] . Briefly, brain tissues were homogenized in 5 volumes of ice-cold PBS (pH 7.2) and centrifuged at 12,000 g for 20 min, at 4 ° C. The supernatant was then collected, and total protein was determined by the Bradford method. Data were acquired using a 96-well plate reader (Bio-Tek instruments Inc., VT, USA). The cytokine concentrations are expressed as picograms cytokine per milligram protein.
Statistics
The locomotor, stereotyped and beam walking behavioral data were presented as the mean ± standard error of the mean (SEM) and analyzed by 2-way repeated measures analysis of variance (ANOVA) for data from tests conducted continuously at different postnatal days, followed by the Student-Newman-Keuls test. Data from gait analysis, immunostaining, and ELISA were presented as the mean ± SEM and analyzed by 2-way ANOVA followed by the Student-Newman-Keuls test. Results with a p < 0.05 were considered statistically significant.
Results
rhIGF-1 Attenuated LPS-Induced Motor Behavioral Deficits
No significant difference was observed between the male and female rats within the same treatment group from P6 to P21. Therefore, data from rats of both sexes were combined and presented here. sures ANOVA for data from tests conducted continuously on different postnatal days, followed by the Student-Newman-Keuls test. * p < 0.05 represents significant differences for the LPS + vehicle group or LPS + IGF-1 group compared with the saline + vehicle group; # p < 0.05 represents significant differences for the LPS + IGF-1 group compared with the LPS + vehicle group.
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Locomotion. Locomotion was measured using the open field test which measures the activity and habituation response of animals on placement in a novel environment [28] . The total distance traveled by the animal, reflected by horizontal activity, increased with age until P15 in all groups ( Fig. 1 a) . LPS treatment resulted in hyperactivity from P13 to P17 compared to the control group ( p < 0.05, Fig. 1 a) . rhIGF-1 treatment significantly decreased the LPS-induced hyperactivity in the LPS + rhIGF-1 group ( p < 0.05, Fig. 1 a) . However, this behavioral deficit was spontaneously reversible, and at P19 there were no significant differences in horizontal activity between LPS and the control rats ( Fig. 1 a) .
The summation of rearing responses and stereotyped behaviors reflect vertical activity [29] . Neonatal LPS exposure significantly increased the vertical activity at P14 and P21, as indicated by the increased number of rearing events ( p < 0.05, Fig. 1 b) at P14 and P21, and stereotyped behaviors at P21 ( p < 0.05, Fig. 1 c) , compared with the control group. Administration with rhIGF-1 significantly decreased the LPS-induced increase in rearing events and stereotyped responses ( p < 0.05, Fig. 1 b, c) .
Beam Walking Test. Consistent with our previous study using the round wood beam [6] , all pups from the control group succeeded in the beam walking test by P17, and the beam walking latency decreased with age ( p < 0.05, Fig. 2 a) . LPS administration resulted in reduction of success in the beam walking test (all LPS-injected groups succeeded on P21), and increase in latency to travel across the round beam ( p < 0.05, Fig. 2 a) . rhIGF-1 treatment significantly advanced the success in the beam walking test (all of the LPS + rhIGF-1 group succeeded on P19), and improved LPS-induced impaired performance in the beam walking test ( p < 0.05, Fig. 2 a) .
Gait Analysis. LPS administration resulted in an increase in foot length ( p < 0.05, Fig. 2 b) and stride width ( p < 0.05, Fig. 2 c) , and a reduction of total spreading (spreading of toes 1-5) ( p < 0.05, Fig. 2 b) and stride length ( p < 0.05, Fig. 2 c) . The tests of gait abnormalities and beam walking deficits were conducted for the evaluation of nigrostriatal lesions in rodent models [31] . rhIGF-1 treatment significantly improved LPS-induced impaired gait performance ( p < 0.05, Fig. 2 b, c) .
rhIGF-1 Ameliorated LPS-Induced Loss of TH-Immunoreactive Neurons
Positive staining of TH was used to detect dopamine neurons in the SN, VTA, and OB. No significant differences in TH and NeuN staining were observed between the ipsilateral (left) and the contralateral side (right) in the P21 rat brain. Therefore, data from both sides were averaged and presented in the paper. The corresponding 448 intensity profiles of TH expression were presented under the photomicrograph of TH+ cells in the different brain regions. Consistent with our previous reports [5, 6] , neonatal LPS exposure significantly reduced the number of TH+ neurons in the SN ( p < 0.05, Fig. 3 b, e, g), VTA ( p < 0.05, Fig. 4 b, e, g), and OB of P21 rats ( p < 0.05, Fig. 5 b, e, g) by 44, 32, and 22, respectively. The LPS-induced reductions of TH+ cells were observed at a greater degree in the SN of the P21 rat brain ( p < 0.05, Fig. 6 i) . However, LPS exposure did not significantly alter the total number of NeuN+ cells (neurons) in the SN ( Fig. 3 h) , VTA ( Fig. 4 h) , and OB ( Fig. 5 h) , suggesting that LPS did not result in actual neuronal cell death in these areas. Therefore, the reduction in the number of TH+ cells may be a consequence of phenotypic suppression of TH expression. rhIGF-1 treatment significantly attenuated the LPS-induced reduction in the number of TH+ neurons in the SN ( p < 0.05, Fig. 3 c, f, g ), VTA ( p < 0.05, Fig. 4 c, f, g ), and OB of P21 rats ( p < 0.05, Fig. 5 c, f, g ). LPS-induced chronic inflammation has been found in other central catecholaminergic neurons in the LC of the pons [23, 24] . Therefore, the positive staining of TH in the LC was also determined in the P21 rat brain. LPS exposure significantly reduced the number of TH+ neurons in the LC of P21 rats by 48% ( p < 0.05, Fig. 6 b, e, g) but did not significantly alter the total number of NeuN+ cells (neurons) in the LC ( Fig. 6 h) . rhIGF-1 treatment significantly attenuated the LPS-induced reduction in the number of TH+ neurons in the LC ( p < 0.05, Fig. 6 c,  f, g ). 
rhIGF-1 Decreased LPS-Induced Increase in COX-2 Expression
Neonatal LPS-induced inflammatory responses can be identified by the increase in the number of COX-2+ cells in the SN ( p < 0.05, Fig. 7 b, d, g, j) , VTA, OB, and LC of P21 rats ( p < 0.05, Fig. 7 j) compared with the control rats ( Fig. 7 a, j) . Double staining showed that most COX-2+ cells in the SN, VTA, OB, and LC were colocalized with NeuN+ neurons ( Fig. 7 f as the example in SN) . Some of COX-2+ cells were colocalized with TH+ cells ( Fig. 7 i) . The TH+ cells were 36.5 ± 2.58, 18.8 ± 2.38, 17.25 ± 1.42, or 38.3 ± 1.93% colocalized with COX-2+ cells in the SN, VTA, OB, and LC, respectively ( Fig. 7 j) . The LPS-induced increase in COX-2+/TH+ cells was observed at a greater degree in the SN and LC of the P21 rat brain ( p < 0.05). Treatment with rhIGF-1 significantly Fig. 7 c, j) .
rhIGF-1 Suppressed LPS-Induced Chronic Microglia Activation
Neonatal LPS exposure resulted in a sustained microglial activation, as indicated by the increased number and features of activated morphology of Iba1+ cells. In the control rat brain, few Iba1+ cells were detected. These detected cells only exhibited resting status, which was characterized by smaller rod-shaped soma with fine and ramified processes ( Fig. 8 a, g) . A significantly increased number of Iba1+ cells was found in the SN, VTA, OB, and LC of the LPS-exposed rat brain ( p < 0.05, Fig. 8 b, h, j) . Moreover, the majority of these Iba1+ cells showed typical features of activated microglia, i.e. bright staining of an elongated or round-shaped cell body with blunt or no processes [34] (arrows indicated in Fig. 8 b) . rhIGF-1 significantly suppressed LPS-induced microglia activation, as shown by the reduced number of Iba1+ cells in the SN ( p < 0.05, Fig. 8 c,  i, j) , VTA, OB, and LC ( p < 0.05, Fig. 8 j) .
rhIGF-1 Decreased LPS-Induced Inflammatory Responses
Three major proinflammatory cytokines, IL-1β, IL-6 and TNF-α in the SN, VTA, OB, and LC of P6 and P21 rat brain were determined by ELISA. LPS induced robust inflammatory responses in the SN, VTA, OB, and LC of P6 rats, as shown by a strong induction of IL-1β and IL-6 levels ( Fig. 9 a, b) . The elevation of IL-1β levels in the SN, VTA, OB, and LC was sustained in P21 rats ( Fig. 9 c) , but not for IL-6 levels in the P21 rat brain (data not shown). TNF-α was undetectable in the SN, VTA, OB, and LC of the P6 and P21 rat brain (data not shown). Administration of rhIGF-1 reduced the LPS exposure-induced elevation of IL-1β levels in all regions at P21 ( p < 0.05, Fig. 9 c) , but not at P6 ( Fig. 9 a) . However, rhIGF-1 reduced LPS exposure-induced elevation of IL-6 levels in P6 rats ( p < 0.05, Fig. 9 b) .
Discussion
Perinatal LPS exposure-induced inflammation has been shown to impair neonatal brain development in rats shortly after the exposure and also to increase the risk of dopaminergic disorders in animal models of Parkinson disease [2, 3] . Consistent with the results reported in our previous study [5, 6] , neonatal LPS exposure resulted in nigrostriatal dopaminergic neuronal injury ( Fig. 3 ) , and such central inflammation also induced neurological dysfunction including locomotion, beam walking and gait later in life ( Fig. 1 , 2 ) . Gait abnormalities and beam walking deficits have been tested for evaluation of nigrostriatal lesions in rodent models [31] . Gait disturbances such as gait hypokinesia (reduction in stride length) and motor fluctuations caused by a degeneration of dopaminergic neurons in the SN (the source of dopamine in the nigrostriatal motor pathway) are commonly observed in Parkinson disease patients [35] . Neonatal LPS exposure impaired the development of locomotor activity in the rat which has been correlated with the maturation of neurotransmitter systems mediating inhibition and excitation [28] . In addition, the increased locomotor activity in the LPS group indicates that these animals may have a delay of accommodation to this experience with repeated exposure to the field [28] . The studies have shown that disorder in locomotor activity is associated with an abnormal level of dopamine content in the rat brain concomitant with SN injury [36] . Moreover, Parkinson disease is a multisystem disorder, and loss of LC neurons (a source of noradrenaline) also contributes to motor dysfunction in Parkinson disease [35] . It has been reported that moderate LC damage resulted in reduction of mobility, while extensive LC damage resulted in an increase in mobility and correlated with hyperactivity in rodents [24, 37, 38] . The present study shows that neonatal LPS exposure induced chronic inflammation and neuronal injury in the LC area of P21 rats ( Fig. 6 ). Other studies also indicated that LPS treatment leads to brain damage, increases the proinflammatory cytokine protein levels and red, a-d , g ), NeuN+ cells (green, e ), TH+ cells (green, h ), COX-2+ and NeuN+ (yellow, f ), or COX-2+ and TH+ double-labeled cells (yellow, i ). Double labeling (yellow, f ) showed that most COX-2+ cells ( d ) were NeuN+ cells (neurons) ( e , green). Some COX-2+ cells (yellow, i ) were double-labeled with TH+ cells ( h , green). Quantification of the ratio of COX-2+ cells to TH+ cells in the SN, VTA, OB, and LC are shown in j . The results are expressed as the mean ± SEM of 6 animals in each group and analyzed by 2-way ANOVA, followed by the Student-Newman-Keuls test. * p < 0.05 represents significant differences for the LPS + vehicle group compared with the saline + vehicle group; # p < 0.05 represents significant differences for the LPS + IGF-1 group compared with the LPS + vehicle group; & p < 0.05 represents significant differences for the LPS + vehicle group in VTA or OB regions compared with the LPS + vehicle group in the SN. gene expression, and reduces TH immunoreactivity and gene expression in both the SN and LC [23, 24] .
Neuronal inflammation has been observed in dopaminergic neurons as evidenced by the colocalization of TH+ and COX-2+ cells in the SN ( Fig. 7 ) . Neonatal LPS exposure produced injury in the nigrostriatal dopaminergic system, as indicated by the phenotypic suppression of TH expression in neurons at the SN of P21 rats ( Fig. 3 ) . However, LPS exposure did not alter the total number of NeuN+ neurons ( Fig. 3 c) and did not increase the FluoroJade B+ staining either, which sensitively and specifically binds to degenerating neurons (data not shown) in the SN of P21 rats. Therefore, most COX-2+ cells were colocalized with NeuN+ cells, but not all of COX-2+ cells colocalized with TH+ cells in the SN ( Fig. 7 ) . Neonatal LPSinduced neuronal damage was also observed in VTA ( Fig. 4 ) , OB ( Fig. 5 ) , and LC regions of P21 rats ( Fig. 6 ) . The current data indicated that dopaminergic neurons in the SN were relatively vulnerable to LPS exposure and resulted in more neuronal inflammation, as indicated by fewer TH+ cells ( Fig. 6 i) and more COX-2+ cells, than that in the VTA and OB ( Fig. 7 j) . Possible mechanisms that have been reported show that the increased ion levels in SN dopaminergic neurons may enhance the vulnerability of SN [39, 40] , and higher expression of G substrate VTA dopaminergic neurons may cause relative protection of VTA [40, 41] . Moreover, altered calcium homeostasis is also suggested to render SN dopaminergic neurons particularly susceptible to degeneration [42] . Neuroinflammation-induced elevated levels of pro in flammatory cytokines and oxidative stress lead to neuronal Ca 2+ dysregulation which may contribute to the selective vulnerability of SN and LC in Parkinson disease [24, 42, 43] . In addition, destruction of noradrenergic neurons in the LC may precede the damage to the nigral cells which has been suggested to influence the rate of dopaminergic neuron loss in the SN [44] .
IGF-1 is the main trophic factor in the central nervous system. It plays an important role during early brain development, including promoting neuronal growth, cellular proliferation, differentiation, myelination, synapse formation, and enhancing secretion of various neurotransmitters in the developing nervous system [8, 9] . The perinatal absence of IGF-1 is lethal and a decrease in IGF-1 may cause brain atrophy, brain abnormalities, and loss of neurons [45] . Lower levels of IGF-1 have been reported in different inflammatory conditions in human preterm neonates (sepsis) [46] and LPS-treated animals [45, 47] . The insufficient perinatal IGF-1 following LPS may contribute to the brain abnormalities and demyelination. Our previous studies have shown that exposure to LPS in P5 rats resulted in white matter injury and intranasal IGF-1 administration protected against LPS-induced white matter injury and sensorimotor disturbances in the juvenile rat [16] . The present study further demonstrates that intranasal IGF-1 provides protection against neonatal LPS exposure-induced brain dopaminergic ( Fig. 3-5 ) and noradrenergic neuronal injury ( Fig. 6 ) , and motor behavioral disturbances ( Fig. 1 , 2 ). In addition, it has been reported that IGF-1 is elevated in nigrostriatal dopaminergic neurons (A9), compared to mesocorticolimbic dopaminergic neurons (A10), which may explain the relative vulnerability of A9 to toxins [48] .
Our previous study found that IGF-1 coadministered with LPS through intracerebral injection at a low dose (0.5 μg per pup) protects the rat brain from LPS-induced white matter injury [49] . However, some adverse effects such as increased hemorrhage and increased infiltration of polymorphonuclear cells due to the breaking down of the BBB were observed following coinjection of IGF-1 with LPS [49] . Intracerebral injection of IGF-1 does not appear to be a practical approach for clinical use due to its invasive nature. Therefore, the noninvasive intranasal treatment approach provides a more practical alternation for IGF-1 administration. No hemorrhage or increased polymorphonuclear cell infiltration was found in the rat brain following intranasal treatment of IGF-1 [16] . The physiological levels of IGF-1 in serum are approximately 456 500 ng/mL in rats [50] , and the IGF-1 levels in CSF are about 1% of the IGF-1 levels in serum [50] . However, the IGF-1 levels in adult rat olfactory bulbs and in the adolescent rat hippocampus are approximately 800 pg/mg [51] and 5 pg/mg [50] , respectively. Consistent with our previous study [16] , rhIGF-1 administration through the intranasal route efficiently reached the rat brain, including OBs (approx. 2,000 pg/mg), striatum (approx. 1,000 pg/ mg), and SN (approx. 500 pg/mg) within 30 min ( Fig. 1 ) . Mechanisms involved in the delivery of IGF-1 through intranasal administration are not yet completely understood. LPS treatment in early life causes a long-term enhancement of BBB permeability and white matter damage in rats [52] . In the current study, no significant differences in rhIGF-1 concentrations were observed between the treatment groups within the respective brain regions, i.e. the concentrations of rhIGF-1 in the same brain region were not affected by the LPS treatment. This suggests that penetration of intranasally infused rhIGF-1 into the brain might not need to cross the BBB. Furthermore, other studies also indicated that [ [14, 15] . This observation is consistent with other suggestions that intranasal administration may bypass the BBB to deliver and target drugs to the central nervous system along the olfactory and trigeminal neural pathways, reducing systemic exposure and side effects [14, 15] .
To further investigate the mechanisms of the neuroprotective effects of IGF-1, the neuronal oxidative stress level was measured in the current study. Our results show following LPS injection, the concentration of IL-6 in the SN, VTA, OB, and LC was elevated compared with the control group, but not in the P21 rat. rhIGF-1 attenuated the LPS-induced increase in the concentration levels of IL-6 in the SN, VTA, OB, and LC of P6 rats. The results are expressed as the mean ± SEM of 6 animals in each group and analyzed by 2-way ANOVA, followed by the Student-Newman-Keuls test. * p < 0.05 represents significant differences for the LPS + vehicle group or LPS + IGF-1 group compared with the saline + vehicle group; # p < 0.05 represents significant differences for the LPS + IGF-1 group compared with the LPS + vehicle group.
that neonatal administration of IGF-1 decreased neuronal oxidative stress by suppressing LPS exposure-induced neuronal COX-2 expression in the rat SN, VTA, OB and LC regions at P21 ( Fig. 7 ) . Our data also show that IGF-1 treatment reduced neonatal LPS exposure-induced activation of microglia ( Fig. 8 ) , and elevation of proinflammatory cytokines such as IL-6 and IL-1β in the SN, VTA, OB, and LC regions ( Fig. 9 ) . IGF-1 has been shown to modulate neonatal immune responses in maturation processes and inflammation by suppressing proinflammatory Th1 cytokine IL-6 and stimulating anti-inflammatory Th2 cytokine IL-10 [53, 54] . Increased IGF-1 production through liposomal IGF-1 gene transfer has been shown to regulate pro-and anti-inflammatory cytokine expression in the burn wound and improve healing, suggesting that IGF-1 decreases local inflammation [55] . It was found that exogenous IGF-1 decreases LPS-induced brain cytokine expression via the downregulating of glia activation and inducing an endogenous growth factor [12, 13] . IGF-1 is also considered to have multiple neuroprotective properties, as a result of its autocrine functions in the brain and the control of neuronal excitability, nerve cell metabolism and cell survival [10, 11] . Several studies have shown that intranasally delivered IGF-1 protects against cerebral hypoxic-ischemic injury [17] [18] [19] , LPS-induced white matter injury in the developing rat brain [16] , and other neurodegenerative damages [20, 21] by activation of intracellular signaling cascades such as the phosphatidylinositol-3 kinase/Akt pathway, which phosphorylates glycogen synthase kinase-3β and several other targets critical to cell survival [20, 22] . Activation of phosphatidylinositol-3 kinase/Akt also leads to reduction of mitochondrial reactive oxygen species, and enhanced mitochondrial levels of Akt and mitochondrial-encoded complex IV subunit [22] . It has been hypothesized that development of resistance to IGF-1 leads to weakening of neuroprotective signaling and may underlie all of the major pathogenic routes in the central nervous system [10, 56] .
In summary, IGF-1 delivered through the intranasal route in the neonatal rat provides long-lasting protection against LPS-induced dopaminergic and noradrenergic neuronal injury, and ameliorates LPS-induced motor behavioral dysfunction in juvenile rats. The protective effects of IGF-1 are associated with the decrease in microglia activation and reduction of neuronal oxidative stress by suppressing neuronal COX-2 expression in the rat SN, VTA, OB, and LC. Intranasal administration of IGF-1 is a noninvasive method which efficiently delivers IGF-1 into the brain and provides a feasible posttreatment approach for brain injury associated with central inflammation and has potential for great significance in the clinical setting.
